Drug combo effective against recurrent ovarian cancer; New 'oncopig' billed as advance for cancer R&D; p53 mechanism could be harnessed to fight cancer;

> A UCLA team found that using a combination of birinapant with a chemotherapy eliminated a population of cells responsible for recurrent ovarian cancer. Birinapant sensitizes CA125-negative cells to the chemotherapy by restoring apoptosis, or programmed cell death, said Dr. Sanaz Memarzadeh, a senior author of the study and a UCLA gynecologic cancer surgeon. Release

> Geneticists at the University of Illinois have developed a new "oncopig" animal model for cancer which is being billed as a better research tool for cancer diagnostics as well as new therapy development. Release

> A mechanism used by p53 to trigger apoptosis could be harnessed into a new therapy for fighting cancer. Release

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.